{"name":"Alfasigma S.p.A.","slug":"alfasigma-s-p-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PMF104","genericName":"PMF104","slug":"pmf104","indication":"Inflammatory bowel disease (IBD) or related gastrointestinal inflammatory conditions","status":"phase_3"}]}],"pipeline":[{"name":"PMF104","genericName":"PMF104","slug":"pmf104","phase":"phase_3","mechanism":"PMF104 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.","indications":["Inflammatory bowel disease (IBD) or related gastrointestinal inflammatory conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxPSEE1ODZ4dEJ2U2NxNjczaFgwRHBQd1pZenNvUjE0ME5IdHZJeUE3RHZrTUxUR1RuMnBya19PWmNHVjJJbmRkWFFjWGFHY3otbm94dVJiSS0tbWE5cFdaY281ak1IbXgxRVRjVVhwazFFbFdSNWFET3lBWDBMZHJ3UXlCLXk0VU11aUhCakZvR1M1bG5rSHYzeGdPdmVKRDU2UDU4LVdHYzdaUUc4ODNkdVduYWxDb2dUbzh0SGh6N2VTQ2t6TE9xSFQ5VzdXM0xFdGN2WmpmQ2FBYm5aZ3ptc0RSVnlHRTZSX1R1MXV0UE10cWczMC1RSTlkOHpTb3VQblZ3dUxCZnVYdDNxWXpURF8zSktoQUdFaXM0bXhET1dpUGc?oc=5","date":"2026-01-14","type":"pipeline","source":"prnewswire.com","summary":"Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease - prnewswire.com","headline":"Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNM3U5UUhUVmZVSnMtX2VHSkQ4S1AwazZ3NzFuWEhJalJldXRLMGw0eU8tT2tNdVBMemtxMC1EV0JWdWVYM1NTamZKTzY0WllhamY5bEtDX0NTX1BUSGJYSFlkM0k4bHVtcHNSU09DT1k4LUZJM2NlMlJ0ZkFFSXJ2ekhkM1FkdDFxUGtjRnZCTGl5ajdLSmFDczlYa3g5THd2cTVCTkxlVENFUmRxRlctbnFUVXUwb1pBR3FyelpSdGtFOGFhR2hDOWNlclBDck5ISnRGWjNNMk1JeEF0aTBJ?oc=5","date":"2025-09-11","type":"pipeline","source":"Citeline News & Insights","summary":"Intercept Withdraws Ocaliva From US, The Last Market For The PBC Drug - Citeline News & Insights","headline":"Intercept Withdraws Ocaliva From US, The Last Market For The PBC Drug - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQa3dDNFlydUh4ZkV5dGZlbUlONGNGSzBFYzF1Uk1qU0dWMEtpbmRFeEFRTV8zaG9VaUEydHN2WVB4MUcwRzUwOGlUcnJ3Mzc4dTFMdjNOWnlZekNDTjRtQjNBOXhxbExkN2d1ZUMybG1QVjRNQVNWYzZPNkE2cFE1Nng0UmlnRVNiQ1FTX0RaUzh1MXgwZXRCcjRfa1c5aHM?oc=5","date":"2024-01-02","type":"deal","source":"European Biotechnology Magazine","summary":"Alfasigma SpA signs €170m deal with Galapagos NV - European Biotechnology Magazine","headline":"Alfasigma SpA signs €170m deal with Galapagos NV","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPQV9ycjFXUmN6bHlwcU42eW1VVU5ncHdWT2JpaUJMaXItRi1idDhzTTk2Z19kTGJSY2c1eV9pZUhDSkpKU3ZITHpaOVM5bTBxQmZvUVFKdFVGLTRfZUNBMmtoUmx2TDh0VU1pakFFdTRYc0loQ05Zel9MYnptMnhVX09OMTBTcl9kWEQzeDNUN3hwQmVxZHBzZldTV3h5aXNhaGlmWnduOWdNZDdwLTVDU0tmNV9wRjFYQUFDYUh5VQ?oc=5","date":"2023-11-08","type":"pipeline","source":"businesswire.com","summary":"Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc. - businesswire.com","headline":"Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE1aWjVxaGo2Zjd5Mk9McTBzZHZhNDE2NUR3N2Q2TkZ1YW1uQXk4Q1RaUWYwYUNtVnpTbHJxeG1KWldHTWxNbnZudDVWOXJtRElZdzhETkE1WGpVdVZGenVIMTJFRk56RGhWMEV2Sng0VlhWSHdKeG1QaQ?oc=5","date":"2023-11-01","type":"deal","source":"pharmaphorum","summary":"Alfasigma to buy Galapagos’ JAK drug for up to €170m - pharmaphorum","headline":"Alfasigma to buy Galapagos’ JAK drug for up to €170m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNOVoxdjhKQUhQNlpOSEZkWFhDVnQ0eVBZYllESnN1U0JFTW45ekw3YjZkZTUyb1EzRlRxSDBwVzFSV2FfLUQzbjZCVGtqdTVHNVNydDFmbHdmcUdfLUV5cHZjWE42UVcwRWh5anNMVUYwY1RQSXRnNjR1VjJMSkQyYTkwdWJ3RG1BQUhoa0dQRDdzZmk2ZmZYMkRMb3dVWlE?oc=5","date":"2023-10-31","type":"pipeline","source":"European Biotechnology Magazine","summary":"Alfasigma SpA set to take over Galapagos programme - European Biotechnology Magazine","headline":"Alfasigma SpA set to take over Galapagos programme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQWU5xbjB2d0Q4RU9tNmh5ellDQjk5bGNHdXFVdmNHTG5pVF9JRVFrM0wtNWZRSkx2X21FbXhMMTYyQnA1SWpkYy1vUDBYMG05OWtId0RMNTlSTnZaQ0lKZTE1MzNRYUp1U3Q0UTdTSWxkSm9WTjNzN1E5YkJJWlpKQThIWGRRMXk1Z203RDEyY21zUFN1UU51S1pXUQ?oc=5","date":"2023-09-26","type":"deal","source":"BioSpace","summary":"Alfasigma Buys Beleaguered Intercept Pharmaceuticals in $800M Cash Deal - BioSpace","headline":"Alfasigma Buys Beleaguered Intercept Pharmaceuticals in $800M Cash Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wJBVV95cUxQVDVtMmtTd3pNVjJuS1A1dzJqMHI3RjdlTWt1Mm9GajhoQzV4bU81dEZ4dUU5VkpXVVNicHl1X1Y4ckg1NjhoeWZLUlNzVHJJWXNkUGFrY3NRZW1CLU1VMTZJNTY3aTVqcGlOZWFSNnFnSGtCVk1aSEdDWktqNkFuRGxNMnQ3cFZPV2tvbTkzWm1samdzQXZ1eE5oM3hHN3JFclMtWkJLUmZyR3lBZF9paFYzVUptYjVUN1Z3MHBaeHdwQ0daY09SVEF2S2V0T2dlVnNJRy1UNUEydEUwNjh2NEdySWRzYnRiMkN4dHZINEZpX3ZxbVduSGhaT01FUUFzRHNpZk5YZU5oOFU0VXJ5OW1seDg5Rm51UV9PN2VsTWVMMEE2aG5VTGpSMHB4dXJhNUJ0d1JlM2x1Ql9Ob0o0R2tmSlJWR1ctanQ4UHFmRnpGUDBuNElqN1gwVDB1VHc?oc=5","date":"2023-09-26","type":"deal","source":"GlobeNewswire","summary":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00 - GlobeNewswire","headline":"Alfasigma to Acquire Intercept Pharmaceuticals for $19.00","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-06-27","type":"pipeline","source":"Fedaiisf","summary":"ALFASIGMA, avviata procedura di licenziamento per 456 lavoratori, 274 Informatori scientifici | Fedaiisf - Fedaiisf","headline":"ALFASIGMA, avviata procedura di licenziamento per 456 lavoratori, 274 Informatori scientifici | Fedaiisf","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQeGJsM2J2M2hVUXRBOEt4OC1XSUo3NzdiNzhjeTZBM3Zxc3NHc3A5eDZLNU1LU2NQMlZCbmJGTTJDTHhvcEJpZ1pvVHk0TExCNld1bnhIdW1zOTMzUnF3MFFpbDN3RkYweWZWN2xFSWRDS1pyazEzNFljek1mZVBxdkdoTzRZRE9VOHY4b085RHhTblMtOWh3VnlQZjNlRGV1b3lnZGJ1NlFweDEzTTFJV0hGWXNfMGJhcDg0bzdOUkFTSVVkM2RWNUp1d3VxbGJTNUJvajRuV0paVEZ6?oc=5","date":"2022-10-20","type":"deal","source":"PR Newswire UK","summary":"ALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANY - PR Newswire UK","headline":"ALFASIGMA ACQUIRES THE ENTIRE SHARE CAPITAL OF SOFAR, AN ITALIAN PHARMACEUTICAL COMPANY","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNenZhbWlYR1NTVml2RXRwaUx1TXRIM3ZyNVdHQWNaaGU5dzRiREhtT3VsUmxldUNReTZNQlR6bzd5Wl9FNDdPUk9DcEtnU0VSaWtTZHdEODZ4cmxLcjZPR1N2QzdyZk9kTy11S1ZUZ1Rjc1BSR1ZYUTVqSnZpV1VPeFZPV2pac3FKRk1BeE9YM1VMNlZrTjNzWTlFUFRNbHktNGg0czNUc3JNTUJXVC05RjNHY3E3eUdHcWg5ekpBYVdRSG56aUZjdnFmTEpRT1lVTmh6N3l6YU91Tm5NN0J5M2M0OXBvR2x0Yjh1dlp3cw?oc=5","date":"2022-08-02","type":"pipeline","source":"PR Newswire UK","summary":"ALFASIGMA ANNOUNCES THE AGREEMENT FOR THE ACQUISITION OF 100% OF SOFAR, ITALIAN PHARMACEUTICAL COMPANY - PR Newswire UK","headline":"ALFASIGMA ANNOUNCES THE AGREEMENT FOR THE ACQUISITION OF 100% OF SOFAR, ITALIAN PHARMACEUTICAL COMPANY","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}